Samsodien, HalimaNgilirabanga, Jean Baptiste2021-08-162024-05-152021-08-162024-05-152021https://hdl.handle.net/10566/15059Doctor Pharmaceuticae - DPharmTreatment of the human immunodeficiency virus (HIV) and tuberculosis (TB) infections have become very complicated due to the advent of drug resistance. Drug combinations offer an alternative approach to reducing the emergence of drug resistance. Pharmaceutical co-crystals have provided the pharmaceutical industry with the ability to optimise the physicochemical properties of active pharmaceutical ingredients (APIs) while preserving the biological activity. Pharmaceutical co-crystals are formed between APIs and suitable co-formers that are biologically safe or even a second or third API.enHIV/AIDSTuberculosisInfectious diseasesDrug resistanceSolid dispersionsUniversity of Western Cape